《半日總結》恆指跌121點 科技股偏軟 聯想集團造淡
美上月生產者物價指數超預期,道指隔晚(16日)跌431點或1.3%,港股早市反覆偏軟。恆指低開29點,初段曾升69點至21,056點,其後再度向下,中午前曾跌169點一度低見20,818點,半日跌121點或0.6%,報20,866點;國指跌38點或0.5%,報7,051點;恆生科技指數跌63點或1.5%,報4,303點。大市半日成交金額441.45億元,滬、深港通南下交易半日淨流入6.7億及8.21億元人民幣。
主要科技股隨外圍科技股走軟,騰訊(00700.HK)跌0.8%報379.5元。阿里巴巴(09988.HK)跌1.5%報100.6元,美團(03690.HK)、小米(01810.HK)及百度(09888.HK)各跌逾2%,快手(01024.HK)及嗶哩嗶哩(09626.HK)各跌1.7%及1.4%,京東(09618.HK)跌1.1%。
其他科技股方面,新東方在線(01797.HK)及金山雲(03896.HK)各升2.6%及3%,金蝶(00268.HK)、美圖(01357.HK)及金軟(03888.HK)各跌3.8%至4.8%。個人電腦生產商聯想集團(00992.HK)公布業績前,半日股價跌2.9%報6.8元。
汽車股方面,蔚來(09866.HK)跌2.9%,華晨中國(01114.HK)升4.7%。重型卡車及機械股造好,中國重汽(03808.HK)及中聯重科(01157.HK)各升6.3%及4.9%。鋁相關股中鋁(02600.HK)及中國宏橋(01378.HK)各升3.3%及3.6%。
消費及內需股個別發展,頤海(01579.HK)、貓眼(01896.HK)及維他奶(00345.HK)各跌3%至4%。
醫藥股山東新華製藥(00719.HK)新注射液獲內地仿製藥一致性評價,股價升15.4%。早前發盈喜的愛康醫療(01789.HK)半日股價升6.7%。華潤醫藥(03320.HK)升5.6%。
金融股方面,匯控(00005.HK)升0.2%報58.2元,港交所(00388.HK)及友邦(01299.HK)各跌0.4%及1.4%。昨午公布業績後造好的渣打(02888.HK)升0.4%報70.1元。
超媒體(00072.HK)委任邵忠及鄭志剛為聯席主席,股價急升68%。華興資本(01911.HK)暫時無法與主席兼控股股東取得聯繫,股價跌26.5%報7.35元。香港航天科技(01725.HK)升2.2%,半日成交逾7.15億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.